Veliparib

Veliparib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is used to treat advanced ovarian cancer that has spread to other parts of the body (metastatic) and is used in combination with chemotherapy. Veliparib works by blocking the activity of an enzyme called PARP, which is involved in repairing damaged DNA. By blocking PARP, Veliparib prevents cancer cells from repairing their damaged DNA, which can lead to cell death.

Veliparib is a potential anti-cancer drug undergoing evaluation for the treatment of various cancers, particularly those with specific genetic mutations. Here's a breakdown of its key aspects:

Mechanism of action:

• PARP inhibitor: Veliparib belongs to a class of drugs called poly(ADP-ribose) polymerase (PARP) inhibitors. PARP is an enzyme involved in repairing DNA damage in cells. By inhibiting PARP, veliparib hinders cancer cells' ability to repair their DNA, leading to their death.

Applications:

• Targeted therapy: Veliparib shows promise as a targeted therapy, particularly effective in cancers with mutations in genes like BRCA1 and BRCA2. These genes play a crucial role in DNA repair, and their dysfunction makes cancer cells more susceptible to the effects of PARP inhibitors.
• Solid tumors: Research is ongoing, but veliparib is being investigated for treating various solid tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer (NSCLC).

Current status:

• Investigational drug: Veliparib is not yet a commercially available medication. It's still undergoing clinical trials to determine its efficacy and safety for specific cancer types.

Administration:

• Oral medication: Veliparib is being studied as an oral medication, offering a potentially convenient way to deliver the drug to patients.